Stockscreener 앱 받기
3.66
4.57%
0.16
시간 외 거래:
3.67
0.010
+0.27%
전일 마감가:
$3.50
열려 있는:
$3.5
하루 거래량:
331.48K
Relative Volume:
0.38
시가총액:
$278.26M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-13.27%
1개월 성능:
-87.47%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$3.47
$3.96
1주일 범위
$3.41
$5.35
52주 변동 폭
$2.601
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
MENS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
3.66 | 266.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jyong Biotech Ltd 주식(MENS)의 최신 뉴스
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update - MarketBeat
After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value - simplywall.st
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech Ltd.(NasdaqGM: MENS) added to NASDAQ Biotechnology Index - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry By Investing.com - Investing.com Nigeria
Jyong Biotech 'not aware' of any material information amid share price movement - MSN
Jyong Biotech in Talks With Funds Interested in Buying Shares - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry - Investing.com
Jyong Biotech in talks with investment funds for purchasing co's ordinary shares - marketscreener.com
Jyong Biotech ‘not aware’ of any material information amid share price movement - TipRanks
Jyong Biotech Responds to Share Price and Volume Movement - The Manila Times
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week LowHere's Why - MarketBeat
Small U.S. Stocks Decrease; Jyong Biotech Falls Furthest - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Small U.S. Stocks Close Lower; Jyong Biotech Falls Furthest - 富途牛牛
Jyong Biotech (NASDAQ:MENS) Stock Price Down 19.3%Here's What Happened - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap DownWhat's Next? - MarketBeat
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2025. - marketscreener.com
Jyong Biotech Shares Becomes Oversold (MENS) - Nasdaq
Jyong Biotech (NASDAQ:MENS) Trading Down 5.9%Here's Why - MarketBeat
Jyong Biotech Ltd.'s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - MarketBeat
Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - Defense World
Jyong Biotech (NASDAQ:MENS) Shares Gap Down – Here’s Why - Defense World
Taiwan's Jyong Biotech expands regional partnership with MoU signing in Vietnam - BioSpectrum Asia
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3%Time to Sell? - MarketBeat
Jyong Biotech expands regional partnerships, signs MoU with a Vietnam pharmaceutical distributor - marketscreener.com
Jyong Biotech Expands Regional Partnerships, Signs MoU With A Vietnam Pharmaceutical Distributor - TradingView — Track All Markets
Jyong Biotech Expands Regional Partnerships, Signs MOU with - GlobeNewswire
Jyong Biotech (MENS) Stock Analysis Report | Financials & Insights - Benzinga
Jyong Biotech (NASDAQ:MENS) Trading Up 15.1%Here's What Happened - MarketBeat
Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha
Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat
Taiwan's Jyong Biotech announces partnership in Korea to evaluate in‑licensing of plant-derived MCS drugs - BioSpectrum Asia
Jyong Biotech signs letter of intent with South Korean pharma company - Investing.com Australia
Jyong Biotech to Evaluate Licensing Deal for MCS-2 Drug Candidate in South Korea - marketscreener.com
Jyong Biotech signs letter of intent with South Korean pharma company By Investing.com - Investing.com South Africa
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs - The Manila Times
Jyong Biotech (Nasdaq: MENS) LOI to Evaluate MCS-2 Licensing with Korean Pharma - Stock Titan
MCS-8, a Plant-Derived Drug, Reduces Prostate Cancer Incidence vs Placebo - CancerNetwork
Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance
Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results By Investing.com - Investing.com South Africa
Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - marketscreener.com
Jyong Biotech announces completion of primary endpoint statistical analysis for phase II clinical trial of MCS-8 with positive outcomes - MarketScreener
Jyong Biotech Ltd (MENS) 재무 분석
Jyong Biotech Ltd (MENS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):